Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

Measurement of total cfDNA levels, which is a simpler and less expensive biomarker than CTC counts, is associated with PFS, OS and response in MBC, suggesting potential clinical application of a cheap and simple blood-based test.